Clinical Trial Update: DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of DS-1205c with gefitinib in EGFR-mutant metastatic or unresectable non-small cell lung cancer was terminated; results posted previously.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DS-1205c (DS-1205c)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2023-02-08